Improving pregnancy rates in women with endometriosis undergoing IVF treatment
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4
This study is looking at whether a new oral medication can help women with endometriosis have a better chance of getting pregnant through IVF, and it involves comparing the medication to a placebo to see which works better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10700871 on NIH RePORTER |
What this research studies
This research investigates the effects of a new oral medication, a GnRH antagonist, on improving live birth rates in women with endometriosis who are undergoing in vitro fertilization (IVF). The study involves a randomized clinical trial where participants will receive either the medication or a placebo before their IVF treatment. By comparing the outcomes, the researchers aim to determine if this new approach can enhance fertility success for women affected by endometriosis. The study also explores the potential role of specific biomarkers related to endometriosis in predicting treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with endometriosis who are experiencing infertility and are planning to undergo IVF.
Not a fit: Patients who do not have endometriosis or those who are not seeking IVF treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase the chances of live births for women with endometriosis undergoing IVF.
How similar studies have performed: While the use of GnRH agonists has been explored, this approach with GnRH antagonists is novel and has not been previously tested for improving fertility outcomes in women with endometriosis.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Taylor, Hugh Smith — Yale University
- Study coordinator: Taylor, Hugh Smith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.